DAEWOONG CO.,LTD Termination of Southeast Asia pitavastatin supply contract with Abbott, KRW 69,227,120,771
DAEWOONG CO.,LTD· Single Sales/Supply Contract
DAI summary · Not investment advice
Subsidiary Daewoong Pharmaceutical terminated its Southeast Asia supply contract with Abbott worth KRW 69.2 billion, effective 2024-02-28.
Termination amount
KRW 69.2 billion
Key facts
- Terminated contract
- Export supply contract for Daewoong Pitavastatin Calcium tablets in Southeast AsiaProduct supply
- Recent revenue
- KRW 839.7 billionBased on 2015 consolidated financials at the time of the original contract
- % of revenue
- 8.24%
- Counterparty
- ABBOTT PRODUCTS OPERATIONS AG (Switzerland)
- Reason for termination
- Contract terminated by mutual agreement due to changes in the business environment
- Contract period
- Nov 2, 2016 – Nov 2, 2026
- Termination date
- Feb 28, 2024
- Original contract disclosure date
- Nov 3, 2016
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist